Dr. Peeters on the Utility of Aflibercept in CRC

Marc Peeters, MD, PhD
Published: Tuesday, Oct 22, 2013

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the utility of aflibercept in patients with advanced colorectal cancer.

Based on available data, there are two populations where aflibercept could be used. The first group, consisting of patients who rapidly progress on bevacizumab, may benefit from another VEGF-targeting agent. The second subgroup of patients consists of those who could see a better response in the second line, Peeters says.

Previous data demonstrates that it is crucial to directly impact the disease as it evolves quickly, Peeters says. It is also important to induce a response in patients and move to resection in the second-line setting.

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the utility of aflibercept in patients with advanced colorectal cancer.

Based on available data, there are two populations where aflibercept could be used. The first group, consisting of patients who rapidly progress on bevacizumab, may benefit from another VEGF-targeting agent. The second subgroup of patients consists of those who could see a better response in the second line, Peeters says.

Previous data demonstrates that it is crucial to directly impact the disease as it evolves quickly, Peeters says. It is also important to induce a response in patients and move to resection in the second-line setting.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x